BusinessMinerva Neurosciences Reports First Quarter 2018 Financial Results and Business UpdatesBy Nasdaq OMXMay 3, 2018, 11:30 AM UTC
BusinessMinerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business UpdatesBy Nasdaq OMXMar 12, 2018, 11:30 AM UTC
BusinessMinerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018By Nasdaq OMXMar 5, 2018, 1:31 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive DisorderBy Nasdaq OMXDec 21, 2017, 1:00 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia DisorderBy Nasdaq OMXDec 6, 2017, 1:30 PM UTC
BusinessMinerva Neurosciences Reports Third Quarter 2017 Financial Results and Business UpdatesBy Nasdaq OMXNov 6, 2017, 12:30 PM UTC
BusinessMinerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive DisorderBy Nasdaq OMXSep 5, 2017, 12:00 PM UTC
